

DAFTAR PUSTAKA

- Adams, V. R., dan Arnold, S. M., 2015, *Pharmacotherapy Handbook*, Ninth Edition, Section 11, 643, The McGraw-Hill Companies, United States of America.
- Adams, V. R., dan Hecht, K. A., 2020, *Pharmacotherapy : A Pathophysiologic Approach*, Eleventh Edition, Section 19, 146, The McGraw-Hill Companies, United States of America.
- Alberg, A. J., Ford, J. G., Samet, J. M., 2007, Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition), *Chest*, **132**(3), 29-55.
- Aldossary, S. A., 2019, Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin, *Biomedical & Pharmacology Journal*, **12**(1), 7-15.
- American Cancer Society, 2019, *How Is Chemotherapy Used to Treat Cancer*, <https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html> diakses pada 15 Oktober 2023.
- American Lung Association, 2023, *Radiation Therapy for Lung Cancer*, [https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/treatment/types-of-treatment/radiation-therapy#:~:text=Lung%20cancer%20radiation%20therapy%20uses,tumor%20\(internal%20implant\).](https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/treatment/types-of-treatment/radiation-therapy#:~:text=Lung%20cancer%20radiation%20therapy%20uses,tumor%20(internal%20implant).) diakses pada 15 Oktober 2023.
- American Lung Association, 2023, *Targeted Therapy for Lung Cancer*, <https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/treatment/types-of-treatment/targeted-therapies> diakses pada 15 Oktober 2023.
- Ardakani, M. T., Kazemian, K., Salamzadeh, J., Mehdizadeh, M., 2013, Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country, *Iranian Journal of Pharmaceutical Research*, **12**, 175-182.
- Asmara, O. D., Tenda, E. D., Singh, G., Pitoyo, C. W., Rumende, C. M., Rajabto, W., Ananda, N. R., Trisnawati, I., Budiyo, E., Thahadian, H. F., Boerma, C., Faisal, A., Hutagaol, D., Soeharto, W., Radityamurti, F., Marfiani, E., Romadhon, P. Z., Kholis, F. N., Suryadinata, H., Soeroto, A. Y., Gondhowiarjo, S. A., Geffen, W. H., 2023, Lung Cancer in Indonesia, *Journal of Thoracic Oncology*, **18**(9), 1134-1145.
- Ayenew, W., Asmamaw, G., dan Issa, A., 2020, Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies, *BMC Pharmacology and Toxicology*, **21**(63), 1-13.

- Badan POM, 2020, *Modul Farmakovigilans untuk Tenaga Profesional Kesehatan Proyek "Ensuring Drug and Food Safety"*, Badan Pengawas Obat dan Makanan, Jakarta.
- Blower, P., Wit, R. D., Goodin, S., Apro, M., 2005, Drug–Drug Interactions in Oncology: Why Are They Important and Can They be Minimized?, *Critical Reviews in Oncology/Hematology*, **55**(2), 117-142.
- Boisdron-Celle, M., dan Gamelin, E., 2000, [*Pharmacology of platinum analogs-taxanes interactions*], <https://pubmed.ncbi.nlm.nih.gov/11082720/#:~:text=Cisplatin%20reduces%20paclitaxel%20plasma%20clearance,paclitaxel%20is%20administered%20before%20cisplatin>. diakses pada 27 Maret 2024.
- BPOM, 2014, *Informatorium Obat Nasional Indonesia (IONI)*, Kementerian Kesehatan RI, Jakarta.
- Brewer, L., dan Williams, D., 2012, *Drug Interactions that Matter*, *Medicine Clinical Pharmacology*, **40**, 371-375.
- Cancer Therapy Advisor, 2017, *Non-Small Cell Lung Cancer Treatment Regimens*, https://media.chemotherapyadvisor.com/documents/261/nsclc_r1017_65225.pdf diakses pada 24 Maret 2024.
- Cancer Therapy Advisor, 2019, *Non-Small Cell Lung Cancer Treatment Regimens*, https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2019/10/NSCLC_1019.pdf diakses pada 24 Maret 2024.
- Cancer Therapy Advisor, 2022, *Small Cell Lung Cancer Treatment Regimens*, <https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2022/01/Small-Cell-Lung-Cancer-Treatment-Regimens-0122.pdf> diakses pada 24 Maret 2024.
- Castillo, J. J., Vincent, M., Justice, E., 2012, Diagnosis and Management of Hyponatremia in Cancer Patients, *The Oncologist*, **17**, 756 –765.
- Dasari, S., dan Tchounwou, P. B., 2014, Cisplatin in Cancer Therapy: Molecular Mechanisms of Action, *European Journal of Pharmacology*, **740**, 364-378.
- Delord, J. P., Puozzo, C., Lefresne, F., dan Bugat, R., 2009, Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors, *Anticancer Research*, **29**, 553-560.
- Drugs.com, 2023, *Cisplatin Interactions*, <https://www.drugs.com/drug-interactions/cisplatin.html> diakses pada 15 Oktober 2023.
- Drugs.com, 2024, *Cisplatin Interactions*, <https://www.drugs.com/drug-interactions/cisplatin.html> diakses pada 15 Maret 2024.

- Fatimah, U. N., 2022, *Mitos Seputar Kemoterapi*, https://yankes.kemkes.go.id/view_artikel/1366/mitos-seputar-kemoterapi diakses pada 28 Oktober 2023.
- Fauziah, K., 2019, *Patologi Anatomi RSUP Dr. Hasan Sadikin Bandung Periode 2012-2017*.
- Food and Drug Administration, 2015, *Cisplatin Injection*, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s0831bl.pdf diakses pada 25 Maret 2024.
- Gassler, N., Zhang, C., Wenger, T., Schnabel, P. A., Dienemann, H., Debatin, K. M., Mattern, J., dan Herr, I., 2005, Dexamethasone-Induced Cisplatin and Gemcitabine Resistance in Lung Carcinoma Samples Treated Ex Vivo, *British Journal of Cancer*, **92**, 1084-1088.
- Ghosh, S., 2019, Cisplatin: The First Metal Based Anticancer Drug, *Bioorganic Chemistry*, **8**, 1-20.
- Gragossian, A., Bashir, K., Bhutta, B. S., Friede, R., 2023, *Hypomagnesemia*, [https://www.ncbi.nlm.nih.gov/books/NBK500003/#:~:text=Hypomagnesemia%20is%20an%20electrolyte%20disturbance,%2FL\).%5B1%5D](https://www.ncbi.nlm.nih.gov/books/NBK500003/#:~:text=Hypomagnesemia%20is%20an%20electrolyte%20disturbance,%2FL).%5B1%5D) diakses pada 27 Maret 2024.
- Guthrie, B., Makubate, B., Hernandez-Santiago, V., dan Dreischulte, T., 2015, The Rising Tide of Polypharmacy and Drug-Drug Interactions: Population Database Analysis 1995–2010, *BMC Medicine*, **13**(1), 1-10.
- Herdianingsih, S., Muhtadi, A., Lestari, K., dan Annisa, N., 2016, Potensi Interaksi Obat-Obat pada Resep Polifarmasi: Studi Retrospektif pada Salah Satu Apotek di Kota Bandung, *Jurnal Farmasi Klinik Indonesia*, **5**(4), 288-292.
- Hines, L. E., dan Murphy, J. E., 2011, Potentially Harmful Drug–Drug Interactions in the Elderly: A Review, *The American Journal of Geriatric Pharmacotherapy*, **9**(6), 364-377.
- Jatoi, A., Williams, B., Nichols, F., Marks, R., Aubry, M. C., Wampfler, J., Finke, E. E., Yang, P., 2005, Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort, *Lung Cancer*, **49**, 77-84.
- Jayanti, E., 2013, *Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Paru di Instalasi Rawat Inap RS “X”*, 1-16.
- Kang, H. S., Shin, A. Y., Yeo, C. D., Park, C. K., Kim, J. S., Kim, J. W., Kim, S. J., Lee, S. H., dan Kim, S. K., 2020, Clinical Significance of Anemia as A Prognostic Factor in Non-Small Cell Lung Cancer Carcinoma with Activating Epidermal Growth Factor Receptor Mutations, *J Thorac Dis.*, **12**(5), 1895-1902.

- Kannan, G., Anitha, R., Rani, V. N., Thennarasu, P., Alosch, J., Vasantha, J., Martin J. R., dan Uma, M. R. C., 2011, A Study of Drug-Drug Interactions in Cancer Patients of A South Indian Tertiary Care Teaching Hospital, *Journal of Postgraduate Medicine*, **57**(3), 206-210.
- Kannan, B., Nagella, A. B., Prabhu, A. S., Sasidharan, G. M., Ramesh, A. S., dan Madhugiri, V., 2016, Incidence of Potential Drug-Drug Interactions in a Limited and Stereotyped Prescription Setting - Comparison of Two Free Online Pharmacopoeias, *Cureus*, **8**(11), 1-7.
- Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Inoue, K., Mori, K., Fujii, H., Mano, H., Odgerel, T., Furukawa, Y., 2006, Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro, *Oncol Res.*, **16**(2), 85-95.
- Katzung, B. G., Masters, S. B., Trevor, A. J., 2012, *Basic & Clinical Pharmacology*, 12th Edition, The McGraw-Hill Companies, Inc., New York.
- Khasanah, D. N., 2022, The Risk Factors of Hypertension in Indonesia (Data Study of Indonesian Family Life Survey 5), *JPH Recode*, **5**(2), 80-89.
- Kementerian Kesehatan RI, 2017, *Pedoman Nasional Pelayanan Kedokteran: Kanker Paru*, Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI, 2019, *Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia*, <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/> diakses pada 8 Oktober 2023.
- Kim, S., Lee, H., Park, C. H., Shim, C. N., Lee, H. J., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C., Kim, H. Y., Kang, D. R., 2015, Clinical Predictors Associated With Proton Pump Inhibitor-Induced Hypomagnesemia, *American Journal of Therapeutics*, **22**(1), 14-21.
- Komite Penanggulangan Kanker Nasional, 2015, *Panduan Penatalaksanaan Kanker Paru*, Kementrian Kesehatan Republik Indonesia, Jakarta.
- Kurniawati, F., Yasin, N. M., Dina, A., Atana, S., dan Hakim, S. N., 2020, Kajian Adverse Drug Reactions Terkait Interaksi Obat di Bangsal Rawat Inap Rumah Sakit Akademik UGM, *Jurnal Manajemen dan Pelayanan Farmasi*, **10**(4), 297-308.
- Kusumawardani, N., Yudistra, W., Alie, I. R., 2024, Karakteristik dan Faktor Risiko Pasien Kanker Paru di RSUD Al-Ihsan Provinsi Jawa Barat Tahun 2022, *Bandung Conference Series: Medical Science*, **4**(1), 55-61.
- Lababede, O., Meziane, M. A., 2018, The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams, *The Oncologist*, **23**(7), 844-848.

- Laurell, G., dan Engstrom, B., 1988, The combined effect of cisplatin and furosemide on hearing function in guinea pigs, *Hearing Research*, **38**(1989), 19-26.
- Leeuwen, R. W. F. V., Brundel, D.H.S., Neef, C., Gelder, T. V., Mathijssen, R.H.J., Burger, D.M., Jansman, F.G.A., 2013, Prevalence of Potential Drug-Drug Interactions In Cancer Patients Treated With Oral Anticancer Drugs, *Br. J. Cancer*, **108**, 1071–1078.
- Lindgren, A., Pukkala, E., Nissinen, A., Tuomilehto, J., 2003, Blood Pressure, Smoking, and the Incidence of Lung Cancer in Hypertensive Men in North Karelia, Finland, *American Journal of Epidemiology*, **158**(5), 442-447.
- Mach, C. M., Nguyen, D., Shumway, J., Meaders, K. M., Ludwig, M., Williams-Brown, M. Y., Anderson, M. L., 2017, A Retrospective Evaluation of Furosemide and Mannitol For Prevention of Cisplatin-Induced Nephrotoxicity, *Journal of Clinical Pharmacy and Therapeutics*, **42**, 286–291.
- Manikkuttiyil, C., dan Nguyen, H., 2023, *Megestrol*, <https://www.ncbi.nlm.nih.gov/books/NBK559205/#:~:text=Megestrol%20is%20a%20medication%20used,the%20progestin%20class%20of%20drugs>. diakses pada 25 Maret 2024.
- Magro, L., Moretti, U., dan Leone, R., 2012, Epidemiology and Characteristics of Adverse Drug Reactions caused by Drug-Drug Interactions, *Expert Opinion Drug Saf*, **11**, 83-94.
- Mccune, J. S., dan Frieze, D. A., 2008, *Lung Cancer, Pharmacotherapy : A Pathophysiologic Approach*, Seventh Edition, Section 17, Chapter 132, 2157-2173, The McGraw-Hill Companies, United States of America.
- Medina, P. J., dan Fausel, C., 2008, *Cancer Treatment and Chemotherapy, Pharmacotherapy : A Pathophysiologic Approach*, Seventh Edition, Section 17, Chapter 130, 2085-2119, The McGraw-Hill Companies, United States of America.
- Menkes RI, 2021, Peraturan Menteri Kesehatan Republik Indonesia Nomor 26 Tahun 2021 tentang Pedoman Indonesia Case Base Group (INA-CBG) dalam Pelaksanaan Jaminan Kesehatan, *Kementerian Kesehatan Republik Indonesia*, 56.
- Mollberg, N., Surati, M., Demchuk, C., Fathi, R., Salama, A. K., Husain, A. N., Hensing, T., Salgia, R., 2011, Mind-Mapping for Lung Cancer: Towards a Personalized Therapeutics Approach, *Advances in Therapy*, **28**(3), 1-22.
- Moura, C., Acurcio, F., Belo, N., 2009, Drug-drug interactions associated with length of stay and cost of hospitalization, *J. Pharm. Pharm. Sci.*, **12**, 266–272.

- Murtaza, G., Yasir, M., Khan, G., Azhar, S., Ali, S., Khan, T.M., 2016, Assessment of potential drug – drug interactions and its associated factors in the hospitalized cardiac patients, *Saudi Pharmaceutical Journal*, King Saud University, **24**(2), 220–225.
- National Cancer Institute, 2023, *Cancer Classification*, <https://training.seer.cancer.gov/disease/categories/classification.html> diakses pada 8 Oktober 2023.
- National Cancer Institute, 2023, *NCI Dictionary of Cancer Terms*, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemotherapy> diakses pada 15 Oktober 2023.
- NCCN, 2013, *Non-Small Cell Lung Cancer*, https://www.nccn.org/guidelines/category_1 diakses pada 25 Oktober 2023.
- Nusair, M. B., Al-Azzam, S. I., Arabyat, R. M., Amawi, H. A., Alzoubi, K. H., dan Rabah, A. A., 2020, The Prevalence and Severity of Potential Drug-Drug Interactions among Adult Polypharmacy Patients at Outpatient Clinics in Jordan, *Saudi Pharmaceutical Journal*, **28**(2), 155-160.
- Pirker, R., Wiesenberger, K., Pohl, G., Minar, W., 2003, Anemia in Lung Cancer: Clinical Impact and Management, *Clinical Lung Cancer*, **5**(2), 90-97.
- Rajkumar, P., Mathew, B. S., Das, S., Isaiah, R., John, S., Prabha, R., dan Fleming, D. H., 2016, Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery, *J Clin Diagn Res.*, **10**(7), XC01-XC04.
- Reiss, A. M. M., dan Cassiani, S. H. D. B., 2011, Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil, *Clinics*, **66**, 9–15.
- Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., Kryzanowska, M. K., 2007, Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients, *JNCI Journal of the National Cancer Institute*, **99**, 592–600.
- Roosihermiatie, B., dan Suharmiati, 2012, Gambaran Penggunaan Tembakau/Rokok Pada Tumor/Kanker Paru Di Indonesia, Riset Kesehatan Dasar 2007/2008. *Buletin Penelitian Sistem Kesehatan*, **15**(3), 298–304.
- Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., dan Donehower, R. C., 1991, Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study, *Journal of Clinical Oncology*, **9**(9), 1692-1703.
- Rusdi, N. K., Sari, N. E., Wulandari, N., 2023, Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021, *Jurnal Sains dan Kesehatan*, **5**(3), 313-323.

- Saito, Y., Kobayashi, M., Yamada, T., Kasashi, K., Honma, R., Takeuchi, S., Shimizu, Y., Kinoshita, I., Dosaka-Akita, H., Iseki, K., 2016, Premedication with Intravenous Magnesium Has A Protective Effect Against Cisplatin-Induced Nephrotoxicity, *Supportive Care in Cancer*, **25**(2), 481-487.
- Sardjito.co.id, 2024, *Waspada Gejala Hipokalemia*, <https://sardjito.co.id/2020/02/17/waspada-gejala-hipokalemia/> diakses pada 25 Maret 2024.
- Scott, A., dan Scott, G. N., 2013, Mechanisms of Drug Interactions, *Pharmacy Tech Topics*, **18**(3), 1-24.
- Siddiqui, F., Vaqar, S., Siddiqui, A. H., 2023, *Lung Cancer*, <https://www.ncbi.nlm.nih.gov/books/NBK482357/> diakses pada 10 Oktober 2023.
- Simmons, C. P. L., MacLeod, N., Laird, B. J. A., 2012, Clinical Management of Pain in Advanced Lung Cancer, *Clin. Med. Insights Oncol.*, **6**, 331-346.
- Stockley, I. H., 2008, *Stockley's Drug Interaction*, Eighth Edition, Pharmaceutical Press, London.
- Sugiyono, 2012, *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*, Alfabeta, Bandung.
- Surendiran, A., Balamurugan, N., Gunaseelan, K., Akhtar, S., Reddy, K. S., dan Adithan, C., 2010, Adverse Drug Reaction Profile of Cisplatin-Based Chemotherapy Regimen in A Tertiary Care Hospital in India: An Evaluative Study, *Indian Journal of Pharmacology*, **42**(1), 40-43.
- Syarif, A., Estuningtyas, A., Setiawati, A., Muchtar, A., Arif, A., Bahry, B., Suyatna F. D., Dewoto, H. R., Utama, H., Darmansjah, I., Wiria, M. S. S., Nafrialdi, Wilmana, P. F., Elysabeth, 2012, *Farmakologi dan Terapi*, Edisi ke-5, Seksi 13, 732-768, Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Syarifah, Prasetyaswati, B., dan Utami, M. N., 2020, *Hematologi Dasar I*, PT Cipta Gadhing, Jakarta.
- Tatro, D. S., 2012, *Drug Interaction Facts*, Wolters Kluwer Health Inc., California.
- Tatro, D. S., 2014, *Drug Interaction Facts 2015: The Authority On Drug Interactions*, 1st Edition, Lippincott Williams & Wilkins, Philadelphia.
- Teixeira, J. J.V., Crozatti, M. T. L., dos Santos, C. A., Romano-Lieber, N. S., 2012, Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil, *PLoS ONE*, **7**(10), 1-6.
- Tobias, J., dan Hochhauser, D., 2010, *Cancer and its Management*, 6th Ed., Wiley-Blacwell, London.

- Tumanggor, M. G., 2013, Karakteristik Penderita Kanker Paru Primer Di Departemen Ilmu Penyakit Paru RSUP Haji Adam Malik Medan Periode Januari 2011 - Desember 2012, *Repos USU*, 8-11.
- Venkatesh, K. M., Acharya, S., dan Holla, R., 2021, Assessment of Potential Drug - Drug Interaction among the Patients Receiving Cancer Chemotherapy: A Cross-sectional Study, *Journal of Pharmacology and Pharmacotherapeutics*, **12**(2), 79-85.
- Varalakshmi, K., 2013, Classification of Lung Cancer Nodules using a Hybrid Approach, *Journal of Emerging Trends in Computing and Information Sciences*, **4**(1), 63-68.
- Viktil, K. K., Blix, H. S., Moger, T. A., Reikvam, A., 2007, Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems, *Br. J. Clin. Pharmacol.*, **63**(2), 187-195.
- World Health Organization, 2022, *Cancer*, <https://www.who.int/news-room/fact-sheets/detail/cancer> diakses pada 8 Oktober 2023.
- World Health Organization, 2023, *Cancer*, https://www.who.int/health-topics/cancer#tab=tab_1 diakses pada 8 Oktober 2023.
- World Health Organization, 2023, *Lung Cancer*, <https://www.who.int/news-room/fact-sheets/detail/lung-cancer> diakses pada 8 Oktober 2023.
- Wu, Z. dan McGoogan, J.M., 2020, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China, *JAMA*, **323**, 1239.
- Yamada, K., Yoshida, T., Zaizen, Y., Okayama, Y., Naito, Y., Yamashita, F., Takeoka, H., Mizoguchi, Y., Yamada, K., Azuma, K., 2011, Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey, *Japanese Journal of Clinical Oncology*, **41**(11), 1308-1311.
- Zang, X., dan Kagan. L., 2023, *Physiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics*, <https://www.sciencedirect.com/science/article/abs/pii/S002235492300429X> diakses pada 22 Oktober 2023.
- Zeng, X., Zeng, D., Cheng, J., Xu, C., Sun, C., Long, H., Zhu, B., 2020, Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus, *Medical Science Monitor*, **26**, e921676.
- Zon, A., dan Bednarek, I., 2023, Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions, *MDPI*, **24**(8), 7585.